TUSSICAPS 10mg/8mg CII
Generic Name and Formulations:
Hydrocodone bitartrate 10mg, chlorpheniramine maleate 8mg; as polistirex; ext–rel caps; contains alcohol.
Indications for TUSSICAPS 10mg/8mg:
Cough and upper respiratory symptoms.
1 cap (10mg/8mg) every 12hrs; max 2caps/24hrs.
<6yrs: see Contraindications. 6–11yrs: 1 cap (5mg/4mg) every 12hrs; max 2caps/24hrs.
Children <6yrs of age (risk of fatal respiratory depression).
Respiratory depression. Post–op. Pulmonary disease. Head injury. Increased intracranial pressure. Glaucoma. Asthma. GI or GU obstruction. Acute abdomen. Severe hepatic or renal impairment. Hypothyroidism. Addison's disease. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antitussive + antihistamine.
Additive CNS depression with alcohol, other CNS depressants, tricyclic antidepressants, MAOIs. Paralytic ileus with concurrent anticholinergics.
Nausea, vomiting, CNS and respiratory depression, ureteral and vesical sphincter spasm, chest tightness, abuse potential, anticholinergic effects, rash, pruritis.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL